Fairfax Media network navigation

  • Home
  • Shares
  • Share details

PROGEN PHARMACEUTICALS LIMITED (PGL)


Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!


General Information
Company Name: Progen Pharmaceuticals Limited
Stock Code: PGL
Website: www.progen-pharma.com
GICS Sub-Industry: Biotechnology
Market Cap ($M): 5
Equiv. Shares (M): 25

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.220 $ 0.220 $ 0.220 $ 0.220 $ 0.215 2,800 $ 0.005  2.326 %

Company Overview

Business Description:
Progen Pharmaceuticals Limited (PGL) is a biotechnology company involved in the discovery, development, and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. PGL also provides contract services related to the process development, manufacture and quality assurance of biological products. PGL focuses on two main anti-cancer product developments, which are PG545 and Muparfostat (PI-88).

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2012  A -3.4 -12.6 -- 0.0 0.0 0.0 --
2011  A -6.1 -22.3 -- 0.0 0.0 0.0 --
2010  A -15.8 -57.9 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F 2010 A 2011 F 2012 F
CSL (CSL) $30,453 M 0.0878 0.3215 0.1438 32.6608 24.7155 21.6080 0.0135 0.0170 0.0192
Mesoblast (MSB) $1,716 M -- -- -- -- -- -- 0.0000 0.0000 0.0000
Progen Pharmaceuticals (PGL) $5 M -- -- -- -- -- -- 0.0000 -- --
Starpharma (SPL) $237 M -- -- -- -- -- -- 0.0000 0.0000 0.0000
Sirtex Medical (SRX) $606 M 0.4803 0.9043 0.3573 35.9603 18.8837 13.9124 0.0092 0.0176 0.0235

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PGL -- -- 1.06 -- 2.39
Market 1.13 13.2 0.92 2.50 2.58
Sector 0.65 21.3 2.39 0.55 6.49

Directors
Name Position Start Date
Mr Stuart Bruce James Chairman 01 July 2009
Mr Heng H Tang Non-Executive Director 17 July 2009
Dr Woei-Jia Jiang Non-Executive Director 16 June 2011

Management
Name Position
Blair Lucas Company Secretary
Fleur Lankesheer Director - Business Development and Legal

Substantial Shareholders
Holding Name
2,122,781 (8.59%) Su-Hua Chuang
2,096,482 (8.48%) Medigen Biotechnology Corp.
1,243,251 (5.03%) CCH Investment Corp. and Tzu Liang Huang

Calendar of Events
Date Event
27 February 2014 Report (Interim)
03 December 2013 Report (Annual)
27 September 2013 Report (Annual)
30 August 2013 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.

Advertisement

Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investment Fees

An educational booklet to help you find out everything you must know about investment fees.

More details...

News

Plummeting dollar, budget steal limelight

The Age 18/05/2013 | The sharemarket lost ground this week, slipping 0.6 per cent, but the dollar stole the headlines after dropping like an anvil.

Break-up could breathe new life into News

The Age 18/05/2013 | Analysts say the split into two divisions may lead to a re-rating of the embattled publishing business, writes Colin Kruger.

Wesfarmers shares fall short of their Target

The Age 18/05/2013 | Wesfarmers shares suffered their biggest fall in almost two years after sharply lowering Target's earnings forecast.

China the new competitor in Australia's online sales

The Age 18/05/2013 | As Australia's major retailers increase their online sales channels, pouring millions into their websites, they could face new competition from China's booming e-commerce industry.

China roars along e-tailing superhighway

The Age 18/05/2013 | Mass consumption is coming of age in the internet era, write Richard Cooper and Richard Dobbs.

Delayed return to surplus no worry - what causes it is

The Age 18/05/2013 | Most of those who take a political approach to the budget assume that if it's in deficit, the way you get it back to surplus is to cut government spending or, if you're a really bad person, increase taxes. They forget it's the budget itself that's supposed to do the heavy lifting.

More...

Sponsored Links
Feedback Form